The Annals Take our Readership Survey!
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 26, No. 3, pp. 316-320.
© 1992 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baethge, B.
Right arrow Articles by Goldberg, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baethge, B.
Right arrow Articles by Goldberg, J.


Research Articles

A study of adverse effects of high-dose intravenous (pulse) methylprednisolone therapy in patients with rheumatic disease

BA Baethge, MD Lidsky, and JW Goldberg

OBJECTIVE: To determine the frequency of significant adverse effects associated with high-dose intravenous methylprednisolone therapy (HIVMP) given as methylprednisolone 1 g/d for three consecutive days. DESIGN: Retrospective study of consecutive patients. SETTING: Department of Veterans Affairs Medical Center (VAMC), university teaching hospital, and private outpatient clinic. PATIENTS: Eighty-four patients given HIVMP for systemic rheumatic disease. MEASUREMENTS: Subjective complaints were elicited via a standardized questionnaire that identified adverse effects through organ system review. Medical records were reviewed for adverse effects occurring within two weeks of HIVMP therapy. RESULTS: Two hundred seventy-five HIVMP treatments were examined by either patient questionnaire (76 patients) and/or chart review (78 patients). Sixty-five patients described symptoms after HIVMP treatment. Most symptoms were transient in duration, mild in severity, and required no medical treatment. Chart review found 42 possible complications occurring within two weeks of HIVMP therapy. In 18 instances medical intervention was required for problems that included hypertension, seizures, gastric erosions, sepsis, and other infections. It is impossible to attribute all of the complications to HIVMP alone because of underlying disease, use of other medications at the time of therapy, or both. CONCLUSIONS: HIVMP has an acceptably low risk of significant adverse effects.


This article has been cited by other articles:


Home page
CLIN PEDIATRHome page
S. Takeshita, Y. Kawamura, K. Nakatani, H. Tsujimoto, and T. Tokutomi
Standard-dose and Short-term Corticosteroid Therapy in Immunoglobulin-resistant Kawasaki Disease
Clinical Pediatrics, June 1, 2005; 44(5): 423 - 426.
[Abstract] [PDF]


Home page
PsychosomaticsHome page
K. Wada, N. Yamada, T. Sato, H. Suzuki, M. Miki, Y. Lee, K. Akiyama, and S. Kuroda
Corticosteroid-Induced Psychotic and Mood Disorders: Diagnosis Defined by DSM-IV and Clinical Pictures
Psychosomatics, December 1, 2001; 42(6): 461 - 466.
[Abstract] [Full Text] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 1992 by Harvey Whitney Books Company.